Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

Truist raised the firm’s price target on Verona Pharma (VRNA) to $57 from $44 and keeps a Buy rating on the shares. The firm cites the ...

Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

Yesterday 6:00am ET Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights by GlobeNewswire ...

Ensifentrine (Ohtuvayre) acts as bronchodilator and non-steroidal anti-inflammatory agent. It is formulated as suspension for inhalational route of administration. Ohtuvayre is indicated for the ...

The revenue was entirely generated from sales of Ohtuvayre, the company's sole marketed product. Following these results, H.C. Wainwright maintained a Buy rating on Verona Pharma shares and raised ...